APA (7th ed.) Citation

Garitaonaindia, Y., Khan, S., Friis, R., Kjær, S., Borch, T. H., Ruhlmann, C., . . . Bastholt, L. (2026). Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: A real-world propensity score–matched survival analysis. JNCI: Journal of the National Cancer Institute, 118(2), 261. https://doi.org/10.1093/jnci/djaf263

Chicago Style (17th ed.) Citation

Garitaonaindia, Yago, et al. "Dabrafenib Plus Trametinib Vs Encorafenib Plus Binimetinib in BRAF -mutant Metastatic Melanoma: A Real-world Propensity Score–matched Survival Analysis." JNCI: Journal of the National Cancer Institute 118, no. 2 (2026): 261. https://doi.org/10.1093/jnci/djaf263.

MLA (9th ed.) Citation

Garitaonaindia, Yago, et al. "Dabrafenib Plus Trametinib Vs Encorafenib Plus Binimetinib in BRAF -mutant Metastatic Melanoma: A Real-world Propensity Score–matched Survival Analysis." JNCI: Journal of the National Cancer Institute, vol. 118, no. 2, 2026, p. 261, https://doi.org/10.1093/jnci/djaf263.